INKT · MiNK Therapeutics, Inc. · Webcasts, Transcripts & Audio
$9.34
-0.19 (-1.99%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Nov 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because the completion of anticipated funding is not entirely within our control, we are required to disclose that substantial doubt exists about our ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q.”View the 10-Q filed Nov 12, 2026
Market Cap
$47.95M
Shares
5.13M
Volume · Nov 13
19.03K
Avg daily vol (3M)
14.64K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
MiNK Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for MiNK Therapeutics, Inc. (INKT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-11
MiNK Therapeutics, Inc. (INKT) Q3 2026 Earnings Call
Revenue
$200,000
Diluted EPS
$-0.50
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-13
MiNK Therapeutics, Inc. (INKT) Q2 2026 Earnings Call Transcript
Confident tone
Agent 797 Phase 2 in ARDS / acute lung injury
Multi-drug resistant infections and biothreat
Named Patient paid access program in Brazil
Diluted EPS
$-0.62
Audio
Transcript
Slides
8-K10-Q
Annual General Meeting
Investor event
2026-06-17
MiNK Therapeutics, Inc. (INKT) June 17, 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-15
MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript
Confident tone
ARDS / acute lung injury program
Commercial opportunity and unmet need
C-Further pediatric collaboration / partnerships
Diluted EPS
$-0.57
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-31
MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript
Confident tone
ARDS / hypoxemic pneumonia randomized Phase II trial
iNKT cell platform and clinical durability
Strategic collaborations / partnering
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-12-08
MiNK Therapeutics, Inc. (INKT) Q3 2025 Earnings Call Transcript
Confident tone
AGENT-797 Clinical Data in Solid Tumors
Safety Profile of iNKT Cell Therapy
Platform Biology and Mechanism
Revenue
$0
Diluted EPS
$-0.65
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript
Confident tone
iNKT Platform & Lead Candidate agenT-797
GvHD Prophylaxis Program
ARDS / Respiratory Distress
Diluted EPS
$-1.06
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript
Confident tone
GvHD program and NIAID funding
Solid tumor clinical data (gastric and testicular)
Regulatory pathway and FDA engagement
Diluted EPS
$-0.70
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-18
MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript
Confident tone
Clinical Pipeline / 797 in Oncology
Next-Generation Programs (PRAME-TCR, 215, Neoantigens)
Graft versus Host Disease (GvHD) Program & NIAID Funding
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-14
MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Call Transcript
Confident tone
Graft-versus-Host Disease program
iNKT cell platform and manufacturing efficiency
Agent 797 in gastric cancer (Phase 2)
Diluted EPS
$-0.46
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript
Confident tone
AgenT-797 in ARDS
Bispecific engagers and iNKT combination
MiNK-215 CAR-iNKT preclinical
Diluted EPS
$-0.73
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript
Confident tone
MiNK-215 CAR-iNKT (FAP) preclinical and discovery progress
agenT-797 Phase II gastric cancer trial
Combination strategy with checkpoint / T-cell activators
Diluted EPS
$-1.10
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript
Confident tone
iNKT cell platform and manufacturing capabilities
Phase 2 gastric cancer trial with agenT-797
Colorectal cancer MSS opportunity with bot/bal
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
MiNK Therapeutics, Inc. (INKT) Q3 2023 Earnings Call Transcript
Diluted EPS
$-1.50
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
MiNK Therapeutics, Inc. (INKT) Q1 2023 Earnings Call Transcript
Diluted EPS
$-1.70
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-21
MiNK Therapeutics, Inc. (INKT) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
MiNK Therapeutics, Inc. (INKT) Q3 2022 Earnings Call Transcript
Diluted EPS
$-1.90
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
MiNK Therapeutics, Inc. (INKT) Q2 2022 Earnings Call Transcript
Diluted EPS
$-1.80
Audio
Transcript
Slides
8-K10-Q
Showing 1–18 of 18 webcasts
Key facts
CIK
1840229
CUSIP
603693201
13F (30d)
32 filings
23 filers
Visit website
Investor relations